Continuous Subcutaneous Insulin Infusion Alters MicroRNA Expression and Glycaemic Variability in Children with Type 1 Diabetes

Emma S Scott, Andrzej S Januszewski, Luke M Carroll, Gregory R Fulcher, Mugdha V Joglekar, Anandwardha A Hardikar, Timothy Jones, Elizabeth Davis, Alicia J. Jenkins

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

To determine whether continuous subcutaneous insulin infusion (CSII) vs. multiple daily injections (MDI) therapy from near-diagnosis of type 1 diabetes is associated with reduced glycaemic variability (GV) and altered microRNA (miRNAs) expression. Adolescents (74% male) within 3-months of diabetes diagnosis (n = 27) were randomized to CSII (n = 12) or MDI. HbA1c, 1-5-Anhydroglucitol (1,5-AG), high sensitivity C-peptide and a custom TaqMan qPCR panel of 52 miRNAs were measured at baseline and follow-up (median (LQ-UQ); 535 (519–563) days). There were no significant differences between groups in baseline or follow-up HbA1c or C-peptide, nor baseline miRNAs. Mean ± SD 1,5-AG improved with CSII vs. MDI (3.1 ± 4.1 vs. − 2.2 ± − 7.0 mg/ml respectively, P = 0.029). On follow-up 11 miRNAs associated with diabetes vascular complications had altered expression in CSII-users. Early CSII vs. MDI use is associated with lower GV and less adverse vascular-related miRNAs. Relationships with future complications are of interest.
Original languageEnglish
Article number16656
JournalScientific Reports
Volume11
Issue number1
Early online date17 Aug 2021
DOIs
Publication statusPublished - Dec 2021

Fingerprint

Dive into the research topics of 'Continuous Subcutaneous Insulin Infusion Alters MicroRNA Expression and Glycaemic Variability in Children with Type 1 Diabetes'. Together they form a unique fingerprint.

Cite this